Literature DB >> 1376782

Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure.

M F Rousseau1, J Raigoso, C van Eyll, H Van Mechelen, N R Musso, G Lotti, H Pouleur.   

Abstract

Twenty-six patients with mild to moderate heart failure were studied to determine the effects of epinine infusion (at a rate producing plasma levels similar to those measured after oral administration of 100 mg of the prodrug ibopamine) on left ventricular (LV) function (14 patients), and coronary flow and circulating catecholamines (12 patients). The only significant hemodynamic change at an infusion rate of 0.5 microgram/kg/min was a 9% (p less than 0.05) decrease in systemic vascular resistance (SVR). At an infusion rate of 1 microgram/kg/min (mean free epinine plasma levels 14.3 +/- 3.7 ng/ml), heart rate (HR), dP/dtmax (1,405 +/- 255 to 1,490 +/- 320 mm Hg, NS), (dP/dt)/DP40, and the relaxation rate remained unchanged, but the ejection fraction (EF) increased from 32 to 38% (p less than 0.001), cardiac output (CO) increased, and SVR decreased by 22% (p less than 0.05). In a separate group of 12 patients, epinine infusion at rates of 0.5-1 microgram/kg/min produced no significant changes in coronary blood flow or myocardial oxygen uptake. At these infusion rates, arterial norepinephrine (NE) and dopamine (DA) levels decreased slightly and arterial and coronary sinus epinephrine increased. In conclusion, epinine, at concentrations similar to those achieved during therapeutic use of ibopamine, had negligible effect on myocardial contractility and relaxation rate in heart failure patients. Cardiac pump function was improved by a decrease in SVR rather than by inotropic stimulation. The data also suggest that these low concentrations of epinine may modulate the sympathetic nervous system, but further studies are needed to determine whether this effect could have clinical significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376782     DOI: 10.1097/00005344-199202000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

2.  Effect of epinine on tension of human renal arteries.

Authors:  R H Schwinger; C Schulz; K Brixius; M Böhm; J Müller-Ehmsen; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 3.  Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.

Authors:  Y S Tuininga; D J van Veldhuisen; J Brouwer; J Haaksma; H J Crijns; A J Man in't Veld; K I Lie
Journal:  Br Heart J       Date:  1994-12

Review 4.  Inotropic agents for heart failure: what if digoxin increases mortality?

Authors:  W J Remme
Journal:  Br Heart J       Date:  1994-09

5.  Comparison of captopril and ibopamine in mild to moderate heart failure.

Authors:  H J Dohmen; P H Dunselman; P A Poole-Wilson
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

Review 6.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

7.  Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade.

Authors:  L J van Woerkens; F Boomsma; A J Man in 't Veld; M M Bevers; P D Verdouw
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

8.  Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers.

Authors:  A Daul; M Elter-Schulz; U Poller; F Jockenhövel; K Pönicke; F Boomsma; A J Man in't Veld; R F Schäfes; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

Review 9.  Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.

Authors:  C Spencer; D Faulds; A Fitton
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.